Back to searchBackground Papers0
Result Papers0
Derived Papers0
Unknown Papers3
A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)
NCT02529787
PHASE1INTERVENTIONAL
Genuine Research Center, Egypt
60 participants
Started 2013-02 · Completed 2013-03
Status: Completed (as of 12-23-2025)
Conditions
Healthy
Interventions
Linked Papers (from SciSciNet-V2)
Total Papers3
Background
0Result
0Derived
0Unknown
3Total Citations Per Year
Brief Summary
Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Dexlansoprazole from Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed release Capsules (Takeda Pharmaceuticals America Inc., USA)
Sort by:
Background Papers0
No background papers linked
Result Papers0
No result papers linked
Derived Papers0
No derived papers linked
Unknown Papers3
A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability
1987
2,396 citations
Sample size determination for bioequivalence assessment by means of confidence intervals.
1991
221 citations
On sample size calculation in bioequivalence trials.
2001
115 citations